Beam Therapeutics (BEAM) EBITDA Margin (2019 - 2026)
Beam Therapeutics' (BEAM) quarterly EBITDA Margin came in at 337.81% in Q1 2026, up 125905.0% year-on-year from N/an in Q1 2025, and down 2109.66% on a QoQ basis from 15.29% in Q4 2025.
Beam Therapeutics (BEAM) EBITDA Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of EBITDA Margin data on file, last reported at 337.81% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 125905.0% year-over-year to 337.81% in Q1 2026; TTM through Mar 2026 was 226.58%, a 45089.0% increase from a year earlier, with the FY2025 full-year figure at 274.57%, up 37968.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 337.81%, down from 15.29% in the prior quarter.
- Over the last five years, EBITDA Margin for BEAM reached as high as 42.02% in Q4 2023 and fell as low as 1596.87% in Q1 2025.
- Historically, EBITDA Margin has averaged 704.39% across 5 years, with a median of 577.9% in 2022.
- Across the five-year window, EBITDA Margin soared 333864600 bps in 2022 and tumbled 99663 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 444.1% in 2022, then jumped by 109 bps to 42.02% in 2023, then slumped by 892 bps to 332.71% in 2024, then soared by 95 bps to 15.29% in 2025, then slumped by 2110 bps to 337.81% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 337.81% in Q1 2026, 15.29% in Q4 2025, and 1307.6% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | -337.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -337.81% |
| Dec 31, 2025 | -15.29% |
| Sep 30, 2025 | -1,307.60% |
| Jun 30, 2025 | -1,419.22% |
| Mar 31, 2025 | -1,596.87% |
| Dec 31, 2024 | -332.71% |
| Sep 30, 2024 | -746.40% |
| Jun 30, 2024 | -891.06% |
| Mar 31, 2024 | -1,405.29% |
| Dec 31, 2023 | 42.02% |
| Sep 30, 2023 | -629.72% |
| Jun 30, 2023 | -507.79% |
| Mar 31, 2023 | -408.66% |
| Dec 31, 2022 | -444.10% |
| Sep 30, 2022 | -577.90% |
| Jun 30, 2022 | -492.23% |
| Mar 31, 2022 | -904.00% |
| Dec 31, 2021 | -124.31% |
| Sep 30, 2021 | -9,126.34% |
| Jun 30, 2021 | -982,900.00% |